Newtree S.A. Overview
Newtree Impact is one of the very few listed, retail-accessible vehicles in Europe that specialise in early-growth agri-food technology. It is the former Belgian functional-chocolate company NewTree, converted into an evergreen holding that takes minority stakes of roughly €0.3M to €2.5M in Series A to growth-stage companies and in specialist funds. Its themes are food-tech (alternative proteins, precision fermentation, alternative fats and cocoa), agri-tech (precision agriculture, pollination) and food loss. With about €25M of NAV, €17.5M deployed into 25 lines, no debt and about €10.8M of cash at end-2025, it is still sub-scale. Its distinguishing features are its "société à mission" status (the company says it was the first Belgian financial company to adopt it), an independent Mission Committee, IRIS+-based impact reporting and a model of citizen "crowdlisting" alongside institutional anchors (Wallonie Entreprendre, SFPIM). The investment case rests on portfolio maturation toward profitability and exits, against a backdrop of NAV per share that has slipped since 2023 and a very illiquid share.
What the company does
Newtree SA is an investment holding company. It raises equity from private investors, family offices, institutions and the public, and invests that capital as a minority shareholder in private companies and venture funds working on the agri-food system. Its stated purpose is to fight climate change by changing how food is produced, processed and consumed, while targeting market-rate financial returns.
Company's own description (paraphrased from its 2026 investor materials and website). Newtree Impact presents itself as an investment holding that pairs financial returns with environmental impact. It invests in disruptive technology companies reshaping food systems, organised around three themes: Food-Tech (ingredients and dietary shifts), Agri-Tech (agricultural innovation) and Food-Loss (waste streams and upcycling). It invests at Series A to growth stage using its own impact methodology, which is inspired by the UN Sustainable Development Goals and measured with IRIS+ metrics. The company stresses that it is a holding company and not an investment fund: it invests for its own account and says it does not primarily aim to profit from selling its participations (OGM, 2 Jun 2026; Newtree Impact Investors page).
Independent characterisation. In economic terms the vehicle works like a small, permanent-capital venture fund wrapped in a listed company. Its value lies almost entirely in unlisted minority stakes valued under IPEV guidelines; BDO built its valuation tool and policy. It carries cash on the balance sheet, earns negligible operating revenue and pays its costs (about €0.6M a year) out of capital. Shareholder returns depend on (a) uplifts in portfolio valuations, (b) eventual exits, which the company says will first clear accumulated losses and then be distributed, and (c) whether the share price trades at a premium or discount to NAV on a very thin Euronext Access order book. The legal emphasis on "holding, not fund" places it outside the Belgian and EU collective-investment rules (AIFMD) that would otherwise apply, which keeps costs low but also reduces the formal investor protections a regulated fund would offer.
Business and revenue model
| Revenue / value source | Description | Materiality |
|---|---|---|
| Unrealised valuation changes | Periodic IPEV-based re-measurement of participations, reflected in NAV but not in Belgian GAAP profit (only write-downs are booked) | Main driver of NAV. Revaluations were +€1.0M (2023), −€1.4M (2024) and −€2.8M (2025) per the NAV bridge. |
| Realised gains on exits | Sale of participations | None disclosed to date |
| Interest income | Return on cash | €95k (FY2024); €34k (FY2025) |
| Operating revenue | Minor service and other income | €5k (FY2024); €32k (FY2025) |
| Fees from investors | None. The holding does not charge shareholders management fees or carried interest. Costs are borne by the company; the term sheet cites an annual cost of about 2% of total equity and no carry. The Spreds offer states costs are capped at 1.75% of NAV once NAV exceeds €25M. | OGM 2026 term sheet; Spreds |
Product / service / subscription / licensing mix: not applicable. The company has no product, subscription or licensing revenue at the holding level. The only operating products in the wider group sit in portfolio company Newtree Group SA (chocolate, spreads and office coffee).
Value-chain position, "customers" and end-markets
Value-chain position: a growth-stage capital provider positioned between seed and angel investors and late-stage, strategic or IPO investors. It frequently co-invests alongside specialist VCs and corporates (for example Bel Group, Danone Ventures, PINC, Big Idea Ventures, Beyond Impact).
"Customers" on the capital side: about 750 or more shareholders, comprising founders, family offices, angels, institutions (Wallonie Entreprendre, SFPIM, Noshaq, Whitestone Group, among others) and retail investors who came in through crowdlisting campaigns on Spreds and Ecco Nova (BE and FR).
"Customers" on the asset side: entrepreneurs in Food-Tech, Agri-Tech and Food-Loss.
End-markets indirectly exposed: alternative proteins (plant-based, fermentation, insect), food ingredients (fats, flavours, egg and dairy proteins, cocoa alternatives), precision agriculture, pollination and biodiversity services, aquaculture, animal health (bacteriophages), food-waste analytics, and premium consumer chocolate and coffee.
Operating model and cost base
The holding runs with five operational staff, an Investment Committee of five external members, a Mission Committee of four and a Board of seven. Operating expenses were €573k in FY2025 (salaries €462k, rent and supplies €28k, other €74k, listing fees €9k), plus €57k of depreciation (FY2025 income statement). Management puts opex at 2.3% of NAV in 2025, against 2.2% in 2024 and 2.1% in 2023 and 2022.
Strategy
Stated strategy (themes from the June 2026 OGM and website, paraphrased)
-
Mission: invest in science-driven innovations that address the root inefficiencies of a food system the company says generates about €13 trillion a year in hidden environmental, health and social costs.
-
Dual approach: combine direct minority stakes (Series A to growth, plus opportunistic late-stage and listed equity) with fund commitments for diversification and deal-flow visibility.
-
No trade-off on impact: the company says it seeks to maximise environmental and financial returns together rather than merely mitigate ESG risk.
-
Democratising impact investing: make private-market impact exposure accessible to retail investors through listing and crowdlisting.
-
Scale targets (term sheet): €50–100M of equity, 35–40 portfolio companies, tickets of €0.5–2.5M, target IRR of 12% (term sheet) or 15% (deck "at a glance"), and a holding horizon described as indefinite but 10–15 years in practice.
Strategic initiatives (last 24 months)
| Initiative | Date | Description | Status |
|---|---|---|---|
| Public crowdlisting (Belgium) | May–Aug 2024 | First retail campaign; about €2M raised through Spreds and Ecco Nova | Completed |
| €10M capital raise with institutional anchors | Dec 2025 | €8.7M private placement led by WE and SFPIM, plus €1.3M first cross-border BE–FR crowdlisting with 295 investors | Completed |
| Société à mission status and Mission Committee | 2024–2025 (date n/d) | Company says it is the first Belgian financial company with this status | In place |
| Annual Impact Report (first edition, 2025) | 2,025 | Uses IRIS+ methodology with planetary boundaries as its framework | Published |
| Newtree Group professionalisation | 2,025 | Operating Partner J-F Cambier appointed CEO of Newtree Group; €200k tranche invested | Ongoing |
| Diversification into agri-tech and food waste | 2025–2026 | Ubees (pollination), Orbisk (food waste); stated 2026 priority | Ongoing |
| Belgian deployment alongside institutions | 2,026 | Stated objective following WE and SFPIM entry | Planned |
| Secondary liquidity among registered holders | 2,026 | Organise secondary transactions to offset the thin float | Planned |
| Next capital increase | 2,026 | "Upcoming capital increase planned" (OGM 2026); size and terms n/d | Planned |
| Investor meeting | 26 Nov 2026 | Annual investor gathering | Scheduled |
Medium-term targets and guidance
| Target | Value | Source |
|---|---|---|
| Target IRR | 15% (deck "at a glance"); 12% (term sheet); 10–15% over 10–15 years (Ecco Nova 2024) | OGM 2026; Ecco Nova |
| Projected NAV by 2032 (no new capital) | €59.5M, 2.3x, implied IRR 12.6% | OGM 2026 |
| Target equity / AUM | €50–100M | OGM 2026 term sheet |
| Target portfolio size | 35–40 companies | OGM 2026 term sheet |
| Cost cap | 1.75% of NAV above €25M of NAV (Spreds); about 2% of total equity (term sheet) | Spreds; OGM 2026 |
| Portfolio profitability milestones | Heura EBITDA+ Q1 2026; Fable EBITDA+ during Q2 2026; Ubees consistently positive from Q2 2026; CropX first positive quarter Q2 2026 and full year 2027 | OGM 2026 |
Formal earnings guidance: none is issued.
Products & Services
For an investment holding, the "product" is the portfolio. Section 5.1 catalogues every disclosed participation. Section 5.2 catalogues the consumer products of portfolio company Newtree Group, which continue the original NewTree brand.
Investment portfolio (all disclosed lines)
| # | Company / fund | Country | Theme | What it does | Newtree ticket | Investee capital raised | First invested | CEO / lead |
|---|---|---|---|---|---|---|---|---|
| 1 | Newtree Group SA | BE | Food-Tech | Premium organic, Fairtrade, carbon-neutral chocolate and coffee brand; described as a climate-friendly food platform | €2,250,000 | Spin-off | 2,021 | Benoît de Bruyn & G. de Walque (site); J-F Cambier CEO (2025) |
| 2 | Heura Foods | ES | Food-Tech | Plant-based meat brand rooted in Mediterranean food culture; reached positive EBITDA in Q1 2026 | €1,750,000 | €4.9M (site); a €40M round in Feb 2024 was linked to an Upfield alliance | 2,023 | Marc Coloma |
| 3 | Aqua-Spark | NL | Agri-Tech (fund / coop) | Evergreen fund investing across the sustainable aquaculture value chain | €1,200,000 | AUM €294M | 2,020 | Amy Novogratz & Mike Velings |
| 4 | Alt. Nutrition Funds | US / Europe | Food-Tech (funds) | VC and growth funds focused on alternative-protein solutions | €1,000,000 + €500,000 | AUM €300M | 2021 onward | — |
| 5 | Algama Foods | FR | Food-Tech | Microalgae-based ingredients, including egg replacers | €1,004,420 | €13M | 2,022 | Alvyn Severien |
| 6 | EvodiaBio | DK | Food-Loss / Food-Tech | Precision-fermented natural aromas and flavours; raised €6M in Dec 2025 | €960,365 | €6.4M (site) | 2,022 | Camilla Kloss Fenneberg |
| 7 | CropX | IL / US | Agri-Tech | Data-driven farm management and soil sensing; launched CropX Vision AI monitoring tool; first EBITDA-positive quarter expected Q2 2026 | €763,818 | $25M (Series C) | Oct 2023 | Tomer Tzach |
| 8 | Onego Bio | FI | Food-Tech | Animal-free egg white (ovalbumin) via precision fermentation; FDA approval reported for its Bioalbumen | €750,000 | $40M | 2,024 | Maija Itkonen |
| 9 | Standing Ovation | FR | Food-Tech | Animal-free casein via precision fermentation; R&D partnership with Bel Group; 7 patents in 3 families | €750,000 | €30M (site); €46M equity plus €8M non-dilutive cumulative per deck | Q1 2026 | Yvan Chardonnes |
| 10 | Yeastup | CH (tech.eu lists BE) | Food-Tech | Protein and fibre ingredients upcycled from brewer's spent yeast; first 40-hectolitre industrial unit launched | €630,000 | €9.5M | 2,024 | Daniel Gnos |
| 11 | Proteon Pharmaceuticals | PL | Agri-Tech | Bacteriophage-based microbiome protection to combat antibiotic resistance in animals | €600,275 | $25M | 2,021 | Prof. Jarosław Dastych |
| 12 | Perfat Technologies | FI | Food-Tech | Patented oleogel fat alternatives; Newtree co-led the Sep 2025 Series A | €600,000 | €2.5M (site); $2.93M Series A per CB Insights | Sep 2025 | Jyrki Lee-Korhonen |
| 13 | New School Foods | CA | Food-Tech | Whole-cut plant-based salmon fillets using patented technology | $600,000 | $12M | 2,023 | Chris Bryson |
| 14 | Orbisk | NL | Food-Loss | AI and computer vision that measure and cut food waste in professional kitchens | €500,000 | €3.5M (extension) | 2026 (date n/d) | Anastasia Dellis |
| 15 | Cubiq Foods | ES | Food-Tech | Fat replacers for alternative proteins. Has filed for bankruptcy (OGM 2026). | €500,000 (SAFE bridge) | €5M | 2,022 | A. Montefeltro & Dr R. Revilla |
| 16 | Agri Seed Fund (unnamed) | US | Agri-Tech (fund) | Pre-seed to Series A agri-food tech VC | $500,000 | Fund size $75–100M | 2,022 | — |
| 17 | Foreverland | IT | Food-Tech | Cocoa-free chocolate alternative ("Choruba") from fermented carob; claims price below €4/kg | €350,000 | €6M | Mar 2026 | Massimo Sabatani |
| 18 | Ubees | FR / US | Agri-Tech | Precision beekeeping, hive leasing and biodiversity services; EBITDA-positive since 2024 | €344,000 | €8M | Q4 2025 – Q1 2026 | Louis Delelis-Fanien |
| 19 | Atomo Coffee | US | Food-Loss | Bean-free upcycled coffee; pivoted toward prebiotic coffee | €314,441 | $40M | 2,022 | Andy Kleitsch |
| 20 | Protix | NL | Food-Tech / Food-Loss | Insect ingredients for feed and food | €299,879 | €40M | 2,021 | Kees Aarts & Tarique Arsiwalla |
| 21 | Fable Foods | AU | Food-Tech / Food-Loss | Plant-based meat from discarded shiitake mushrooms; entered Waitrose UK, reaching 1,500+ stores on three continents | €284,495 | $10M | 2,022 | Michael Fox |
| 22 | Clay Capital (fund) | — | Funds | Sector VC fund | — | — | 2,024 | — |
| 23 | Three sector VC funds (2025) | — | Funds | Food-tech funds | n/d (part of €2.4M deployed in 2025) | — | 2,025 | — |
| Country | € tickets (k) | $ tickets (k) |
|---|---|---|
| Belgium | 2,250 | 0 |
| Spain | 2,250 | 0 |
| France | 2,098 | 0 |
| Netherlands | 2,000 | 0 |
| Finland | 1,350 | 0 |
| Denmark | 960 | 0 |
| Israel / US (CropX) | 764 | 0 |
| Switzerland | 630 | 0 |
| Poland | 600 | 0 |
| Italy | 350 | 0 |
| Australia | 284 | 0 |
| United States | 1,814 | 500 |
| Canada | 0 | 600 |
Headline ticket sizes are as shown on Newtree Impact's portfolio pages and may be initial tickets or cumulative amounts. USD-denominated tickets are shown in USD. "Capital raised" is the investee's round or cumulative raise as stated by Newtree Impact.
Count reconciliation: the company reports 17 direct lines and 8 funds. The list above shows 18 named direct companies, including Orbisk, which was added after the deck, and Cubiq, which is now bankrupt. Fund lines are only partly named.
Summary of headline tickets by country (derived from the table; € and $ amounts shown separately, not converted).
Newtree Group consumer products (portfolio company)
| Product line | Description | Specifications / claims | Price (where shown) | Channel | Source |
|---|---|---|---|---|---|
| Chocolate bars (30g) | Dark chocolate with speculoos; milk chocolate with almonds | Organic, Fairtrade, carbon-neutral, Belgian | €29.95 per pack of 20 × 30g | E-shop (free Belgian delivery from €50) | newtree.com, accessed Oct 2026 |
| "Delectable" gift box | Box of five Latin American origin chocolates, or a custom selection | Single-origin positioning | €23.90 | E-shop | newtree.com |
| Spreads (pâte à tartiner) | Chocolate spreads | Organic, vegetarian, ambient | — | E-shop; B2B | newtree.com; food.be |
| Neapolitans and pralines | Small chocolates, also sold as private label (e.g., for Exki) | Organic | — | B2B in BE, DK, FR, ES, SE, UK | food.be |
| Newtree Coffee (office coffee) | Sustainable coffee service for companies with free tasting offer | Organic, Fairtrade, CO2-neutral | — | B2B workplace | newtree.com; student.be job ad |
| Historical functional range (2005–2010s) | 80g bars with plant extracts (Eternity, Vivacity, Tranquility, Pleasure, Sexy, Young, Cocoon, Vigor, Renew, Rejoice, Forgiveness) | 73% cocoa dark; 30–33% milk; no preservatives, colourants or GMOs | — | Grocery, specialty, travel retail | Trade press; USPTO trademark records |
| Historical organic range | Belgian biscuit, cinnamon and ginger bars; waffle cookies | Organic, Fairtrade, high-fibre | — | Grocery (EU, US) | Snack & Bakery |
Financial Narrative
Basis and limitations. Full audited income statements and balance sheets are publicly available for FY2024 and FY2025 only, in Belgian GAAP standalone format (OGM, 2 Jun 2026). For FY2021–FY2023 the company discloses NAV, the NAV bridge, opex and capital deployment, but not full accounts in the sources reviewed. Belgian GAAP books participations at cost less permanent write-downs, so unrealised gains appear only in NAV. Conventional operating metrics (gross margin, EBITDA margin, revenue CAGR, cash conversion cycle) are not meaningful for this business. They are shown blank or marked n/m (not meaningful) rather than invented.
Income statement
Notes: FY2024 year-end shares are taken as about 8.97M, implied by the Ecco Nova II pre-money of €23,330,512.40 at €2.60 per share. FY2025 year-end shares are 12,819,428. Weighted-average share counts and diluted EPS are not disclosed. Vendors report trailing EPS of −€0.21 (MarketInOut) and −$0.23 (PitchBook). The only earlier P&L datapoint in the sources is FY2020 (Craft): gross profit €58k, EBIT −€175k, net loss −€178k, cash €268k, when the business was still in transition. The P&L reconciles: FY2025 = −541 − 57 + 34 − 57 − 2,249 = −2,870 (rounding to −2,869); FY2024 = −466 − 44 + 95 − 5 − 1,470 = −1,890.
Margins. Gross, operating, EBITDA and net margins are not meaningful (n/m) with €5–32k of revenue. Revenue CAGR is also n/m.
Commentary. The FY2025 loss of €2.87M is almost entirely non-cash: €2.25M of write-downs on participations, of which the Cubiq Foods bankruptcy is a disclosed contributor, plus about €0.6M of costs. FY2024's €1.89M loss was likewise driven by €1.47M of write-downs. Cash costs rose 22% in FY2025 (€471k to €573k), mainly salaries (+30%), reflecting hires including Investment Analysts and a Head of Expansion & Impact. Interest income fell from €95k to €34k despite much higher cash at year-end. That points to the €10M raise landing very late in the year (December 2025) and to lower deposit rates. Interest expense rose to €57k even though there is no financial debt; the source is not explained (possibly bank or transaction charges).
NAV-based performance (the economically relevant P&L)
Source: OGM, 2 Jun 2026 (NAV evolution, bridge and key metrics). The year-end 2020 starting point was NAV €2.3M and €1.46 per share. As of 30 Apr 2026 (unaudited estimate) NAV was €26M, €2.01 per share, MOIC 0.87x total and 0.91x excluding funds. MOIC values were read from a chart, and their alignment to years is the analyst's best reading. The FY2024 capital raise of €6.8M combines the €5.4M and €1.4M items shown in the bridge (the March 2024 private placement plus the mid-2024 crowdlisting). Opex differs between the bridge and the key-metrics table for FY2021 (€0.2M versus €0.04M). The two disclosures are inconsistent, and the difference is not explained.
Commentary: the central inflection. NAV per share rose about 47% between end-2020 and end-2023 (€1.46 to €2.15) and then fell 8% over two years to €1.98. Portfolio MOIC fell from 1.14x to 0.84x. Absolute NAV kept growing only because new money came in (€16.8M raised in 2024–2025). The decline lines up with the 2023–2025 downturn in alternative-protein funding: global agri-food tech VC fell from $56.6B (2021) to about $16B a year (2023–2025), according to AgFunder data cited in the deck. That downturn forced down-rounds and failures, including Cubiq. A recovery to €2.01 per share by April 2026 hints at stabilisation. The €2.90 (2024) and €2.60 (2025) issue prices were set well above the NAV per share at the time (€2.09 and €1.98). New investors therefore paid a premium that diluted NAV per share upward for existing holders, and those new investors are currently under water on a NAV basis.
Balance sheet
Notes: The company states the holding has no financial debt, or virtually none. The book value of participations (€13.7M) is below cumulative capital invested (€17.5M) because write-downs are booked while gains are not. NAV (€25.4M) exceeds book equity (€24.4M) by about €1.0M, which is the net unrealised uplift recognised under IPEV but not under Belgian GAAP. Disclosures of the invested amount vary: €17.5M (financial summary), €17.9M (2025 highlights) and €19M (2026 "at a glance", presumably after the Q1 2026 deals).
Cash flow (proxies)
No statutory cash-flow statement is published in the sources. The figures below are management-basis proxies taken from the NAV bridge and investment-pace disclosures.
Commentary: Cash rose €7.2M in FY2025 because €10M was raised while only €2.4M was deployed. The holding enters 2026 with roughly 18 years of opex covered by cash at the current run-rate, or about four to five years of deployment at the 2021–2025 average pace of €3.1M a year. Q1 2026 commitments of €1.1M (Standing Ovation and Foreverland), the Orbisk ticket (€0.5M) and follow-ons in Yeastup and New School Foods mean cash at mid-2026 is likely lower than at year-end. The exact figure is not disclosed.
Ratios (FY2024–FY2025)
Not meaningful or not computable: ROIC, net debt/EBITDA (net cash with negative EBITDA), interest coverage (negative EBIT), asset turnover and cash conversion cycle. NAV total return per share is derived as the change in NAV per share (for example FY2021 = 1.58 / 1.46 − 1). The derived FY2024 ROE of −10.9% matches MarketInOut's −10.84%.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Role | Relationship | Status |
|---|---|---|---|
NEWTREE SA (Newtree Impact) | Listed investment holding | Parent / issuer | Active; Euronext Access Brussels |
Newtree Group SA | Chocolate and coffee brand ("Newtree"); office-coffee service ("Newtree Coffee") | Portfolio participation; described as a spin-off. About €2.25M headline commitment, approved end-2023 and executed in tranches, with €200k invested in 2025. | Active; CEO Jean-François Cambier (from 2025) |
Newtree SARL (Lyon) | Historical French distribution affiliate (2002) | Historical affiliate | Current status not publicly disclosed |
US entities (San Francisco; Grand Haven, MI) | Historical US chocolate operations and café | Historical | Current status not publicly disclosed |
Theme Details
| Theme | Contents | % of capital invested FY2025 | Derived € (M) on €17.5M invested |
|---|---|---|---|
Food-Tech | Alternative proteins, fermentation, alternative fats and cocoa, plant-based foods, insect ingredients, Newtree Group | 76 | 13.3 |
Agri-Tech | Precision agriculture (CropX), pollination (Ubees), aquaculture (Aqua-Spark), animal health (Proteon), agri seed fund | 24 | 4.2 |
Theme Details (Projected NAV contribution 2025→2032 (EUR Mn))
| Theme | Projected NAV contribution 2025→2032 (EUR Mn) |
|---|---|
Starting NAV (31 Dec 2025) | 25.4 |
Food-Tech uplift | 27.0 |
Agri-Tech uplift | 4.9 |
Funds uplift | 2.2 |
Projected NAV 2032 | 59.5 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (EUR K) | — | — | — | 5 | 32 |
Operating expenses (EUR K) | — | — | — | -471 | -573 |
of which salaries (EUR K) | — | — | — | -355 | -462 |
of which office rent and supplies (EUR K) | — | — | — | -26 | -28 |
of which other expenses (EUR K) | — | — | — | -81 | -74 |
of which listing fees (EUR K) | — | — | — | -9 | -9 |
EBITDA, operating profit before D&A (EUR K) | — | — | — | -466 | -541 |
Depreciation and amortisation (EUR K) | — | — | — | -44 | -57 |
Operating income / EBIT, derived (EUR K) | — | — | — | -510 | -598 |
Interest income (EUR K) | — | — | — | 95 | 34 |
Interest expense (EUR K) | — | — | — | -5 | -57 |
Value reductions on participations (EUR K) | — | — | — | -1,470 | -2,249 |
Pre-tax income (EUR K) | — | — | — | -1,890 | -2,869 |
Net income (EUR K) | — | — | — | -1,890 | -2,869 |
EPS basic, derived on year-end shares (EUR) | — | — | — | -0.21 | -0.22 |
Dividends per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Key Financials and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
NAV, year-end (EUR Mn) | 4.6 | 8.9 | 13.9 | 18.8 | 25.4 |
NAV per share (EUR) | 1.58 | 1.91 | 2.15 | 2.09 | 1.98 |
Capital raised in year (EUR Mn) | 2.4 | 4.1 | 4.3 | 6.8 | 10.0 |
Portfolio revaluations (EUR Mn) | 0.1 | 0.3 | 1.0 | -1.4 | -2.8 |
Opex per NAV bridge (EUR Mn) | -0.2 | -0.2 | -0.3 | -0.5 | -0.6 |
Opex per key-metrics table (EUR Mn) | 0.04 | 0.18 | 0.29 | 0.42 | 0.60 |
Opex / NAV (%) | 0.8 | 2.1 | 2.1 | 2.2 | 2.3 |
MOIC, total portfolio (x) | 1.03 | 1.06 | 1.14 | 1.00 | 0.84 |
MOIC excluding funds (x) | 1.00 | 0.99 | 1.11 | 1.06 | 0.85 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (EUR K) | — | — | — | 17,375 | 24,763 |
Cash and cash equivalents (EUR K) | — | — | — | 3,615 | 10,779 |
Receivables (EUR K) | — | — | — | 59 | 83 |
Total current assets (EUR K) | — | — | — | 3,685 | 10,867 |
Financial fixed assets, participations at book (EUR K) | — | — | — | 13,574 | 13,734 |
Formation / establishment costs (EUR K) | — | — | — | 108 | 158 |
Intangible assets (EUR K) | — | — | — | 3 | 2 |
Tangible assets (EUR K) | — | — | — | 5 | 2 |
Short-term debt (EUR K) | — | — | — | 0 | 0 |
Long-term debt (EUR K) | — | — | — | 0 | 0 |
Total debt (EUR K) | — | — | — | 0 | 0 |
Net debt (EUR K) | — | — | — | -3,615 | -10,779 |
Total current liabilities (EUR K) | — | — | — | 99 | 357 |
Paid-in capital (EUR K) | — | — | — | 19,841 | 29,841 |
Retained losses brought forward (EUR K) | — | — | — | -692 | -2,583 |
Shareholders' equity, book (EUR K) | — | — | — | 17,275 | 24,406 |
Goodwill and intangibles (EUR K) | — | — | — | 3 | 2 |
Working capital, derived (EUR K) | — | — | — | 3,586 | 10,510 |
Cumulative capital invested, management basis (EUR Mn) | 4.0 | 7.6 | 10.7 | 15.0 | 17.5 |
Balance Sheet — Cash opex proxy, from P&L
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash opex proxy, from P&L (EUR K) | — | — | — | -471 | -573 |
Capital deployed into investments (EUR Mn) | 2.0 | 3.7 | 3.1 | 4.3 | 2.4 |
Equity raised (EUR Mn) | 2.4 | 4.1 | 4.3 | 6.8 | 10.0 |
Dividends paid (EUR K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (EUR K) | 0 | 0 | 0 | 0 | 0 |
Change in cash (EUR K) | — | — | — | — | 7,164 |
Margin Analysis (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE on year-end book equity (%) | — | — | — | -10.9 | -11.8 |
ROA on year-end assets (%) | — | — | — | -10.9 | -11.6 |
NAV total return per share (%) | 8.2 | 20.9 | 12.6 | -2.8 | -5.3 |
Current ratio (x) | — | — | — | 37.2 | 30.4 |
Debt / equity (x) | — | — | — | 0 | 0 |
Cash / NAV (%) | — | — | — | 19.2 | 42.4 |
Opex / NAV (%) | 0.8 | 2.1 | 2.1 | 2.2 | 2.3 |
Region Overview
| Region | Direct-ticket sum (k, mixed €/$ at face value) | Share of total (%) |
|---|---|---|
Europe (BE, ES, FR, NL, FI, DK, CH, PL, IT) | 12,488 | 75 |
North America (US, CA) | 2,914 | 18 |
Middle East (Israel, CropX) | 764 | 5 |
Asia-Pacific (Australia, Fable) | 284 | 2 |
Share Price & Returns
| Period | Return (%) | Source |
|---|---|---|
1 month | -2.50 | Zonebourse, 16 Oct 2026 |
3 months | -2.50 | Zonebourse |
6 months | -2.50 | Zonebourse |
Year to date 2026 | -18.75 | Zonebourse |
1 year | -24.42 | Zonebourse |
3 years | 2.63 | Zonebourse |
5 years | 21.88 | Zonebourse |
10 years | 95.00 | Zonebourse |
Margin Analysis (%) and Share Price
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Calendar-year share return (%) | 250.00 | -28.57 | 12.00 | 64.29 | 4.35 |
Year-end share price, derived (EUR) | 1.75 | 1.25 | 1.40 | 2.30 | 2.40 |
Year-end NAV per share (EUR) | 1.58 | 1.91 | 2.15 | 2.09 | 1.98 |
Price / NAV at year-end, derived (x) | 1.11 | 0.65 | 0.65 | 1.10 | 1.21 |
Capital Markets Data and Operating Metrics (shares)
| Metric | FY2024 | FY2025 |
|---|---|---|
Trading value (EUR K) | 116 | 357 |
Volume (thousand shares) | 47 | 150 |
Average daily volume (shares) | 445 | 587 |
Valuation Multiples
| Multiple | Newtree Impact | Basis |
|---|---|---|
Market cap (EUR Mn) | 25.0 | 12,819,428 × €1.95 |
Price / NAV (x) | 0.98 | €1.95 / €1.98 (Dec 2025) |
Price / book (x) | 1.02 | €25.0M / €24.4M book equity |
Enterprise value (EUR Mn) | 14.2 | Market cap minus €10.8M cash (Dec 2025); likely understated because cash has since been deployed |
P/E | n/m | Negative earnings |
EV/EBITDA | n/m | Negative EBITDA |
EV/Sales | n/m | Negligible revenue |
Analyst Conclusions
Management guidance and targets
The company issues no earnings guidance. Its forward-looking statements are: target IRR of 12–15%; a projected NAV of €59.5M by 2032 with no new capital (2.3x, 12.6% IRR); EBITDA breakeven milestones at Heura (achieved Q1 2026), Fable (Q2 2026), Ubees (Q2 2026) and CropX (Q2 2026 quarter, full year 2027); growth to €50–100M of equity and 35–40 holdings; and an upcoming capital increase. There is no consensus, as the stock has no analyst coverage.
Bull case
-
Valuation trough plus dry powder. With €10.8M of cash (42% of NAV) deployable after agri-food VC funding fell 71% from its 2021 peak, the 2025–2026 vintages (Perfat, Ubees, Standing Ovation, Foreverland, Orbisk) were bought at reset prices. The April 2026 NAV uptick to €2.01 may mark the turn.
-
Portfolio inflecting to profitability. Four holdings are EBITDA-positive or about to be. Heura is the largest direct food-tech line at €1.75M. That improves write-up potential and the odds of exits within three to five years.
-
Structural cost advantage and institutional anchors. About 2% opex with no fees or carry, together with WE and SFPIM on the register, gives a credible platform to scale toward €50–100M, which would dilute fixed costs and support a NAV premium.
Bear case
-
Value destruction is still unfolding. NAV per share has fallen two years running. Portfolio MOIC is 0.84x after about six years, and 47% of direct lines are early-stage or pre-revenue. Cubiq's bankruptcy may not be the last.
-
Investors paying above NAV. Raising at €2.90 and €2.60 against NAV of €2.09 and €1.98 per share flatters existing holders but leaves recent investors under water. If that becomes visible, future raises, which the model depends on, could stall.
-
Illiquidity and structure. A tiny float on Euronext Access, no exits, no distributions and an unregulated holding wrapper mean shareholders may find it hard to realise value even if NAV rises.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | What to watch |
|---|---|---|
| Investor meeting | 26 Nov 2026 | H1 2026 NAV, cash position, raise terms |
| Next capital increase | Late 2026 / 2027 | Size, price versus NAV, institutional participation |
| Board renewal outcome | Post-June 2026 | Names and independence of the two nominees |
| Portfolio EBITDA milestones | Q2 2026 onward | Confirmation at Fable, CropX, Ubees |
| Further insolvencies or write-downs | Ongoing | Early-stage lines (Algama, Atomo, New School, Perfat) |
| First exit | Unscheduled | Any realised gain would validate NAV marks |
| Newtree Group performance | FY2026 | Revenue and margin under the new CEO; cocoa cost pass-through |
| FY2026 audited NAV | ~Jun 2027 OGM | NAV per share trend versus €1.98 |
| Secondary liquidity programme | 2026–2027 | Mechanism and pricing |
Analyst verdict
Newtree SA is no longer a chocolate company. It is a €25M listed impact-venture holding whose shares trade at roughly NAV (0.98x) on almost no volume. The conversion has been well executed in governance and capital-raising terms. About €30M has been raised from more than 750 holders, two public-sector institutions have anchored the latest round, costs are about 2% of NAV with no carry, and the société-à-mission framework with IRIS+ reporting is ahead of most impact peers in its niche.
The financial record is weaker. Since the 2023 peak, NAV per share has fallen from €2.15 to €1.98, and the portfolio's aggregate MOIC has dropped below 1x (0.84x at end-2025). Belgian GAAP losses widened to €2.9M in FY2025 on €2.25M of write-downs, including the first outright failure (Cubiq). Without exits, the €59.5M NAV projection for 2032 cannot yet be tested. Repeated issuance above NAV has protected NAV per share for existing holders but has priced new money expensively.
The investment question therefore comes down to whether the portfolio will mature. There are positive signals: Heura and Ubees are EBITDA-positive, Onego Bio has FDA approval, Standing Ovation has raised capital alongside Bel and Danone, and the April 2026 NAV estimate ticked up. The company also has unusually high cash (about 42% of NAV at year-end) to deploy at reset valuations. Against that, it has a very thin float, a five-person team, a founder-CEO who has led the company for 25 years, sub-scale tickets and heavy reliance on future capital raises.
For an investor seeking diversified, low-fee, mission-aligned exposure to agri-food technology, and able to hold for a decade without needing liquidity, buying at or below NAV is a defensible entry. For anyone needing liquidity, evidence of realised returns or institutional-grade disclosure, the stock remains speculative. The key tests over the next 12 months are the terms of the next capital raise, the H1 2026 NAV and any first exit.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / notes | Prior roles / education | Age | Compensation |
|---|---|---|---|---|---|
Benoît de Bruyn | Founder & CEO | Board member since 29 Mar 2001; CEO tenure recorded from 31 May 2010 | Founder of NewTree chocolate (2001); chemical engineer by training | About 56, derived from "35 years old" in 2005 press | Not individually disclosed |
Jean-Nicolas Fassin | Secretary General | — | — | — | — |
Nathalie Peeters | Head of Expansion & Impact | — | — | — | — |
Thibaud de Saint-Quentin | Portfolio Advisor; sits on Board and Investment Committee | Board since 31 May 2010 per vendor data | — | — | — |
Lisa Colombo | Investment Analyst | — | — | — | — |
Abhishek Anand | Investment Analyst | — | — | — | — |
Investment Manager | Vacant (recruitment advertised) | 2,026 | Profile sought: 7–10 years of agri-food / bioeconomy investing | — | — |
Jean-François Cambier | Operating Partner; CEO of Newtree Group SA | Hired 2025 | — | — | — |
Board of Directors
| Name | Role | Since | Notes |
|---|---|---|---|
Bruno Colmant | Chairman | — | Belgian economist; opened the June 2026 OGM as Chairman |
Michael Baum | Director | — | Also listed as investor and board member (Caplight) |
Frédéric Pouchain | Director | — | — |
Raymond Vaxelaire | Director | Jan 2007 (recorded 05/01/2007) | Independent non-executive per MarketScreener |
Emilie Dallemagne | Director | — | — |
Udaiyan Jatar | Director | 1 Jun 2011 | Long-standing director from the chocolate era |
Board Committees
| Committee | Members | Role |
|---|---|---|
Investment Committee | Serge Demoulin, Fabian Seunier, Nicolas Saillez, Antoine Duchateau, Alain Balthazart (plus T. de Saint-Quentin as portfolio advisor) | Reviews investment decisions |
Mission Committee | Etienne de Callataÿ (economist; joined 2025), Mathilde Do Chi (regulatory expert), Valentine Papeians (ESG in food), Hugues de Meulemeester (environmental expert) | Oversees the company's mission and impact commitments under its "société à mission" status |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
| 2025 | Jean-François Cambier appointed Operating Partner and CEO of Newtree Group SA | Separates management of the chocolate brand from the holding's CEO |
| 2025 | Etienne de Callataÿ joins Mission Committee | Strengthens economic and impact oversight |
| 2026 | Investment Manager recruitment | Team extension listed as a 2026 objective |
2 Jun 2026 | Two board nominations proposed | Outcome not disclosed |
Major Shareholders
| Holder (as named) | Indicative stake (%) |
|---|---|
Float | 10 |
Founders | 4 |
SFPIM (Belgian federal investment company) | 6 |
Wallonie Entreprendre (Walloon regional investment agency) | 8 |
Whitestone Group | 12 |
Spinnova | 10 |
Noshaq (Liège investment fund) | 13 |
Other nominative (registered) shareholders | 51 |
Competitive Landscape
Key Competitors
| Competitor | Type | Arena | Relative positioning vs Newtree Impact |
|---|---|---|---|
Astanor Ventures (Brussels) | Agri-food tech VC (co-investor in a portfolio round) | Deal allocation | Far larger fund; a Brussels peer in the same niche; institutional rather than retail |
PINC (Paulig) | Corporate VC | Deal allocation | Strategic investor; co-invested in Newtree deals twice |
Big Idea Ventures | Alt-protein VC | Deal allocation | Global alt-protein specialist; co-investor in Perfat |
Beyond Impact | Impact VC | Deal allocation | Co-led Perfat |
European Circular Bioeconomy Fund (ECBF) | Thematic VC | Deal allocation | Larger dedicated bioeconomy fund |
Danone Ventures / Bel Group | Corporate VC / strategics | Deal allocation | Strategic capital with commercial synergies Newtree cannot offer |
Good Startup, Hatch, Peakbridge, Five Seasons Ventures, Blue Horizon | Food-tech VCs | Deal allocation | Specialist funds of varying size |
Quest for Growth (Euronext Brussels) | Listed closed-end VC / growth fund | Investor capital | Longer-listed Belgian retail-accessible VC vehicle with broader tech focus and a regulated status |
Gimv (Euronext Brussels) | Listed private-equity investor | Investor capital | Much larger, diversified, dividend-paying |
Sofina (Euronext Brussels) | Listed investment holding | Investor capital | Global growth-equity holding at multi-billion scale |
Crowdfunding platforms' direct deals (Spreds, Ecco Nova) | Retail co-investment | Investor capital | Single-company retail exposure versus Newtree's diversified wrapper |
Competitor Detail
| Metric | Newtree Impact |
|---|---|
NAV or AUM, latest (EUR Mn) | 25.4 |
NAV per share growth, last FY (%) | -5.3 |
Opex / NAV (%) | 2.3 |
Number of portfolio lines | 25 |
Agri-food focus (% of capital) | 100 |



